Pembroke Management LTD reduced its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 7.4% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 37,437 shares of the biotechnology company’s stock after selling 2,983 shares during the period. Pembroke Management […]
Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have received a consensus recommendation of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among […]
Pitcairn Co. lowered its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,263 shares of the biotechnology company’s stock after selling 290 shares during the period. Pitcairn Co.’s holdings in Repligen […]
Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12-month target price among […]
StockNews.com assumed coverage on shares of Repligen (NASDAQ:RGEN – Get Rating) in a research note published on Thursday morning. The firm issued a sell rating on the biotechnology company’s stock. RGEN has been the topic of several other research reports. Deutsche Bank Aktiengesellschaft cut their price objective on Repligen from $180.00 to $165.00 in a […]